Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T C Chan

Showing results (321-330 of 407) with videos related to

Pageof 41
Sort By:
Cancer Research|January 26, 2013
Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patientsEdwin P Hui, Graham S Taylor, Hui Jia, et al.
Cancer|October 12, 2013
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alphaBrigette B Y Ma, Stephen L Chan, Wing M Ho, et al.
Journal of Gastroenterology and Hepatology|January 26, 2011
Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian populationStephen L Chan, Frankie K F Mo, Philip J Johnson, et al.
Investigational New Drugs|May 9, 2012
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell linesBrigette B Y Ma, Vivian W Y Lui, Crystal S Cheung, et al.
Biochemical Pharmacology|March 12, 2010
An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulationVivian Wai Yan Lui, Cecilia Pik Yuk Lau, Crystal Sao Fong Cheung, et al.
Cancers|March 29, 2023
Frequency of Peripheral CD8+ T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon RadiotherapyShweta Mahajan, Hayri E Balcioglu, Astrid Oostvogels, et al.
Plos One|November 17, 2011
The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumorsXing-sheng Shu, Hua Geng, Lili Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinomaAnthony T C Chan, Mow-Ming Hsu, Boon C Goh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinomaQuynh-Thu Le, Qiang Zhang, Hongbin Cao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography resultsTony S K Mok, Winnie Yeo, Simon Yu, et al.
Pageof 41

Showing results (321-330 of 407) with videos related to

Sort By:
Pageof 41
Cancer Research|January 26, 2013
Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patientsEdwin P Hui, Graham S Taylor, Hui Jia, et al.
Cancer|October 12, 2013
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alphaBrigette B Y Ma, Stephen L Chan, Wing M Ho, et al.
Journal of Gastroenterology and Hepatology|January 26, 2011
Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian populationStephen L Chan, Frankie K F Mo, Philip J Johnson, et al.
Investigational New Drugs|May 9, 2012
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell linesBrigette B Y Ma, Vivian W Y Lui, Crystal S Cheung, et al.
Biochemical Pharmacology|March 12, 2010
An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulationVivian Wai Yan Lui, Cecilia Pik Yuk Lau, Crystal Sao Fong Cheung, et al.
Cancers|March 29, 2023
Frequency of Peripheral CD8+ T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon RadiotherapyShweta Mahajan, Hayri E Balcioglu, Astrid Oostvogels, et al.
Plos One|November 17, 2011
The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumorsXing-sheng Shu, Hua Geng, Lili Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinomaAnthony T C Chan, Mow-Ming Hsu, Boon C Goh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinomaQuynh-Thu Le, Qiang Zhang, Hongbin Cao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography resultsTony S K Mok, Winnie Yeo, Simon Yu, et al.
Pageof 41